This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and
efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib
administered with avelumab maintenance therapy compared with platinum-based chemotherapy
followed by avelumab maintenance therapy in patients receiving first-line treatment for
advanced/metastatic bladder cancer.
Patients will be randomly assigned (1:1) to receive standard of care platinum-based
chemotherapy (with or without the addition of trilaciclib) administered intravenously (IV) in
21-day cycles followed by standard of care avelumab maintenance therapy (with or without the
addition of trilaciclib) administered IV in 14-day cycles.
Patients enrolled in the study will be eligible to receive 4-6 cycles of platinum-based
chemotherapy, and patients without progressive disease (PD) as per Response Evaluation
Criteria in Solid Tumors (RECIST) v1.1 guidelines (i.e., with an ongoing complete response
[CR], partial response [PR], or stable disease) after platinum-based chemotherapy will be
eligible to receive avelumab maintenance therapy until disease progression, unacceptable
toxicity, withdrawal of consent, Investigator decision, or the end of the trial, whichever
comes first.
Patients will be followed for survival approximately every 3 months after receiving the last
dose of study medication.
Inclusion Criteria:
1. Age ≥18 years
2. Histologically documented, locally advanced (T4b, any N; or any T, N 2-3) or
metastatic urothelial carcinoma (M1, Stage IV)
3. Measurable disease as defined by RECIST v1.1
4. No prior systemic therapy in the inoperable, locally advanced, or metastatic setting
including chemotherapy, immune checkpoint inhibitor therapy, targeted therapy, or
investigational agents
5. Archival tumor tissue must be available or a fresh biopsy must be obtained, unless
approved by the Medical Monitor
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
7. Adequate organ function as demonstrated by normal laboratory values
Exclusion Criteria:
1. Prior treatment with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137
or CD137 agonists, or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody
(including ipilimumab), or any other therapeutic antibody or drug specifically
targeting T cell co-stimulation or immune checkpoint pathways in any setting
2. Malignancies other than urothelial carcinoma within 3 years prior to randomization,
except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in
situ of the breast or of the cervix, or low-grade (Gleason ≤6) prostate cancer on
surveillance without any plans for treatment intervention (e.g., surgery, radiation,
or castration)
3. Presence of central nervous system (CNS) metastases/leptomeningeal disease requiring
immediate treatment with radiation therapy or steroids.
4. QTcF interval > 480 msec. For patients with ventricular pacemakers, QTcF > 500 msec
5. Known hypersensitivity or allergy to avelumab, gemcitabine, cisplatin or carboplatin
6. Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥3), any
history of anaphylaxis, or uncontrolled asthma
7. Prior hematopoietic stem cell or bone marrow transplantation, or solid organ
transplantation
8. Pregnant or lactating women
9. Active autoimmune disease that might deteriorate when receiving an immunostimulatory
agent
10. Current use of immunosuppressive medication, EXCEPT for the following:
1. Intranasal, inhaled, topical steroids, or local steroid injection (e.g.,
intra-articular injection)
2. Systemic corticosteroids at physiological doses ≤10 mg/day of prednisone or
equivalent
3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan
premedication)
